Trial · NCT07879768
Acupuncture and Laser Acupuncture for Advanced Non-Small Cell Lung Cancer
NCT07879768, Not applicable, Not yet recruiting, China Medical University, Taiwan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acupuncture and Laser Acupuncture for Advanced Non-Small Cell Lung Cancer. Trials, record NCT07879768. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879768
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acupuncture and Laser Acupuncture for Advanced Non-Small Cell Lung Cancer
- NCT number
- NCT07879768
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 90 participants, estimated
- Lead sponsor
- China Medical University, Taiwan
- Conditions
- Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Interventions
- Needle Acupuncture, Laser Acupuncture, Sham Laser Acupuncture
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Functional Assessment of Cancer Therapy-Lung Trial Outcome Index (FACT-L TOI) at 6-8 Weeks | Baseline (Week 0) and End of intervention (Week 6 to 8) | Assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) Trial Outcome Index (TOI), which combines the Physical Well-Being, Functional Well-Being, and Lung Cancer Subscales. The score ranges from 0 to 84, with higher scores indicating better quality of life and lower symptom burden. |
| Secondary | Change from Baseline in FACT-L Lung Cancer Subscale (LCS) Score at 6-8 Weeks | Baseline (Week 0) and End of intervention (Week 6 to 8) | Assessed using the Lung Cancer Subscale (LCS) of the Functional Assessment of Cancer Therapy-Lung questionnaire, evaluating symptoms such as dyspnea, cough, and chest discomfort. The score ranges from 0 to 28, with higher scores indicating fewer symptoms (better outcome). |
| Secondary | Change from Baseline in Modified Medical Research Council (mMRC) Dyspnea Scale Score at 6-8 Weeks | Baseline (Week 0) and End of intervention (Week 6 to 8) | Assessed using the modified Medical Research Council (mMRC) dyspnea scale to evaluate breathlessness during daily activities. The scale ranges from Grade 0 to Grade 4, with higher scores indicating more severe breathlessness (worse outcome). |
| Secondary | Change from Baseline in General Fatigue Scale - Taiwanese Version (GFS-T) Score at 6-8 Weeks | Baseline (Week 0) and End of intervention (Week 6 to 8) | Assessed using the Taiwanese Version of the General Fatigue Scale (GFS-T) to measure cancer-related fatigue. The total score ranges from 14 to 70, with higher scores indicating greater severity and impact of fatigue (worse outcome). |
| Secondary | Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Global Score at 6-8 Weeks | Baseline (Week 0) and End of intervention (Week 6 to 8) | Assessed using the Pittsburgh Sleep Quality Index (PSQI) global score. The score ranges from 0 to 21, with higher scores indicating poorer sleep quality (worse outcome). |
| Secondary | Change from Baseline in 6-Minute Walk Distance (6MWD) at 6-8 Weeks | Baseline (Week 0) and End of intervention (Week 6 to 8) | Functional exercise capacity measured by the distance walked in meters during a standardized 6-minute walk test (6MWT). |
| Secondary | Change from Baseline in Lowest Oxygen Saturation (SpO2) During 6-Minute Walk Test at 6-8 Weeks | Baseline (Week 0) and End of intervention (Week 6 to 8) | Measured as the lowest percentage of oxygen saturation recorded via pulse oximetry during the 6-minute walk test. |
| Secondary | Weekly Analgesic Consumption in Morphine Milligram Equivalents (MME) | Baseline (Week 0) through Week 8 | Total opioid analgesic consumption calculated as weekly morphine milligram equivalents (MME/week). |
| Secondary | Time to Clinically Meaningful Deterioration in FACT-L TOI | From baseline up to 36 months (or study completion) | Time (in weeks or months) to confirmed clinically meaningful deterioration in the FACT-L Trial Outcome Index, defined as a decrease of at least 5 points from baseline. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07879768
GET https://conductscience.org/api/trials/v1/NCT07879768/registered